{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:40Z","timestamp":1790745340700,"version":"4.1.0"},"reference-count":89,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other agents, including alkylators, immunomodulatory drugs, and monoclonal antibodies, have been incorporated into several regimens. This review summarizes the biological effects and the results of clinical trials investigating PI-based combination regimens and novel investigational inhibitors and discusses the future perspective in the treatment of multiple myeloma.<\/jats:p>","DOI":"10.3390\/cancers12020265","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T11:01:00Z","timestamp":1579863660000},"page":"265","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":189,"title":["Proteasome Inhibitors for the Treatment of Multiple Myeloma"],"prefix":"10.3390","volume":"12","author":[{"given":"Shigeki","family":"Ito","sequence":"first","affiliation":[{"name":"Hematology &amp; Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba-cho 028-3695, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continuous improvement in survival in multiple myeloma: Changes in elderly mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"A randomized comparison of bortezomib with high-dose dexamethasone in relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"US Food and Drug Administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: Head-to head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1535-7163.MCT-04-0338","article-title":"Proteasome inhibitor therapy in multiple myeloma","volume":"4","author":"Chauhan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MOH.0b013e328302c7f4","article-title":"NF-kappaB in the pathogenesis and treatment of multiple myeloma","volume":"15","author":"Li","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"ref_14","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncenonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activety of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Kikuchi","year":"2009","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluate on of the proteasome inhibitor bortezomib in cancer therapy","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdq009","article-title":"Enhancing activity and overcoming chemoresistance in hematologyic malignancies with bortezomib: Preclinical mechanistic studies","volume":"21","author":"Reddy","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjh.14920","article-title":"Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial","volume":"179","author":"Einsele","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomized phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: Randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Oriol","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): A randomized, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/10428190903452826","article-title":"Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma","volume":"51","author":"Corso","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-012-1420-7","article-title":"A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma","volume":"91","author":"Ahn","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_36","first-page":"562","article-title":"Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma","volume":"35","author":"Fu","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.2009.07981.x","article-title":"Phase 2 study of two sequential three drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma","volume":"148","author":"Bensinger","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezo -mib\/dexamethasone in newly diagnosed multiple myeloma","volume":"156","author":"Khan","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomized, open-label, phase 3 trial SWOG S0777","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"Laubach","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_55","first-page":"3274","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Jakobs","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V128.22.4531.4531","article-title":"Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell exapansion: Results from a phase 3 randomized study (POLLUX)","volume":"128","author":"Chiu","year":"2016","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluate on of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry. A"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanism of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (endeavor): A randomized phase 3, open-label, multicenter study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomized, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","article-title":"Phase 1 study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and or refractory multiple myeloma","volume":"33","author":"Papadopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: A phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e000570","DOI":"10.1136\/esmoopen-2019-000570","article-title":"European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy","volume":"4","author":"Tzogani","year":"2019","journal-title":"ESMO Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_73","first-page":"895","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: Long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12185-018-2448-9","article-title":"Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: A multicenter phase II clinical trial","volume":"108","author":"Isoda","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-017-0524-3","article-title":"Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: Clinical and model-based analyses","volume":"12","author":"Gupta","year":"2017","journal-title":"Target Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomized, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BST0380137","article-title":"The therapeutic potential of deubiquitinating enzyme inhibitors","volume":"38","author":"Colland","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2010","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A genomic and functional inventory of deubiquitinating enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1038\/onc.2017.172","article-title":"Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"36","author":"Song","year":"2017","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2370","article-title":"Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases","volume":"13","author":"Lauinger","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Pawlyn, C., Davies, F., Cairns, D., Striha, A., Hockaday, A., Kishore, B., Garg, M., Williams, C., Karunanithi, K., and Lindsay, J. (2019, January 12\u201315). Quadruplet KCRD (carfilzomib, cyclophosphamide, lenakidomide and dexamethasone) induction for newly diagnosed myeloma patients:abstract OAB-002. Proceedings of the 17th International Myeloma Workshop, Boston, MA, USA.","DOI":"10.1016\/j.clml.2019.09.003"},{"key":"ref_89","unstructured":"Voorhees, P., Kaufman, J.L., Laubach, J., Sborov, D., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L., and Anderson, L. (2019, January 12\u201315). Daratumumab + lenalidomide, bortezomib & dexamtehsone improved depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN:abstract OAB-087. Proceedings of the 17th International Myeloma Workshop, Boston, MA, USA."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:44:25Z","timestamp":1760363065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":89,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cancers12020265"],"URL":"https:\/\/doi.org\/10.3390\/cancers12020265","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}